liver disease

GlaxoSmithKline
Biotech

GSK pays $1.2B upfront for Boston's lead liver disease drug

GSK is brushing off dropping a cancer asset on Tuesday by snagging a late-stage liver disease drug for a hefty $1.2 billion upfront.
Ben Adams May 14, 2025 2:53am
layoffs cut staff reduction workforce

NGM Bio cuts 75% of staff, halts midstage liver disease program

May 12, 2025 7:00am
A silver slightly shiny strands of DNA appear against a background of clocks

NewLimit raises $130M to push liver mRNA med into clinic

May 6, 2025 11:00am
Pencil filling out Scantron test form

AIRNA preps for clinical test with $155M series B

Apr 1, 2025 7:00am
arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am
Ship sailing through stormy seas

Arbor sails into rocky gene editing waters with $74M

Mar 18, 2025 6:30am